泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01011 泰凌医药

未开盘 08-24 15:19:16

0.420

+0.060

+16.67%

最高0.450	最低0.400	成交量341.20万
今开0.400	昨收0.360	日振幅13.89%
总市值3.99亿	流通市值3.99亿	总股本9.49亿
成交额137.54万	换手率0.36%	流通股本9.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01011","market":"HK","secType":"STK","nameCN":"泰凌医药","latestPrice":0.42,"timestamp":1787555956575,"preClose":0.36,"halted":0,"volume":3412000,"delay":0,"changeRate":0.16666666666666666,"floatShares":949000000,"shares":949000000,"eps":-0.04221,"marketStatus":"未开盘","change":0.06,"latestTime":"08-24 15:19:16","open":0.4,"high":0.45,"low":0.4,"amount":1375405,"amplitude":0.138889,"askPrice":0.43,"askSize":40000,"bidPrice":0.385,"bidSize":40000,"shortable":0,"etf":0,"ttmEps":-0.033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787621400000},"marketStatusCode":0,"adr":0,"listingDate":1303228800000,"exchange":"SEHK","adjPreClose":0.36,"openAndCloseTimeList":[[1787535000000,1787544000000],[1787547600000,1787558400000]],"volumeRatio":4.812411848758795,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01011","defaultTab":"news","newsList":[{"id":"1103953337","title":"泰凌医药（01011）发布2026财年中期业绩：收入增至2,366.5万元 亏损小幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1103953337","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103953337?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:26","pubTimestamp":1787235964,"startTime":"0","endTime":"0","summary":"2026年8月20日，中国泰凌医药集团有限公司公布截至2026年6月30日止六个月未经审核中期业绩。– 收入为2,366.5万元，同比增加97.2%。– 期内亏损1,653.7万元，较上年同期的1,690.6万元减少36.9万元。– 基本及摊薄每股亏损为人民币2.24分，2025年同期为人民币3.03分。以上财务数据均摘自公司于同日发布的《截至2026年6月30日止六个月中期业绩公告》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660385172","title":"泰凌医药(01011)发布中期业绩，股东应占亏损1843.3万元，同比增加9.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660385172","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660385172?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:25","pubTimestamp":1787235955,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布2026年中期业绩，该集团取得收益2366.5万元，同比增加97.29%;公司拥有人应占亏损1843.3万元，同比增加9.03%;每股亏损2.24分。目前，本集团已构建多维协同的业务矩阵：核心治疗板块以骨科创新药物“特立帕肽”的专业化分销与营销为锚点，辅以特色的骨健康中药及保健产品，形成稳固的业务基石。在此基础上，本集团通过收购人工智能骨健康诊断机器人战略性拓展诊断服务。该等智能设备利用人工智能算法实现骨密度及骨健康风险的高效精准筛查，填补本集团于骨健康早期筛查的业务空白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660937774","title":"泰凌医药(01011)对裁决持有重大异议，已委聘合规法律服务团队启动申请撤销裁决等法定程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2660937774","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660937774?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:47","pubTimestamp":1787064469,"startTime":"0","endTime":"0","summary":"本公司对该裁决持有重大异议，已委聘合规法律服务团队启动申请撤销裁决等法定程序。目前该裁决仍处于可依法申请撤销的法定周期内，相关付款义务尚未进入强制执行阶段。本集团日常营运及现金流目前维持正常状态。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118192891","title":"泰凌医药（01011.HK）披露仲裁裁决：或承担约9,200万元人民币付款义务","url":"https://stock-news.laohu8.com/highlight/detail?id=1118192891","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118192891?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:45","pubTimestamp":1787064330,"startTime":"0","endTime":"0","summary":"泰凌医药8月18日晚间公告称，公司已于2026年7月20日收到中国国际经济贸易仲裁委员会出具的〔2026〕中國貿仲京裁字第1519號仲裁裁决。该裁决要求公司及相关连带方合计支付违约金、相关费用及仲裁分担款共计约人民币92,000,000元。仲裁源于泰凌医药于2020年与北京康辰药业股份有限公司相关主体签署的资产交易项目项下担保安排，相关股权转让已于2020年完成交割。目前该裁决仍处于法定可申请撤销期间，相关付款义务尚未进入强制执行阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139602283","title":"泰凌医药（01011）拟于8月20日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1139602283","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139602283?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:07","pubTimestamp":1786352866,"startTime":"0","endTime":"0","summary":"2026年8月10日，中国泰凌医药集团有限公司（股票代码：01011，以下简称“泰凌医药”）发布公告称，公司董事会将于2026年8月20日（星期四）举行会议。\n本次董事会会议主要议程包括：一是审批泰凌医药及其附属公司截至2026年6月30日止六个月的中期业绩；二是考虑建议派发中期股息（如有）。\n公告显示，截至公告日，公司董事会由执行董事吴铁先生、吴静美女士；非执行董事钱唯博士、钱余女士、楼勇斌先生；以及独立非执行董事余梓山先生、郭芝聪先生、赵玉彪博士组成。\n泰凌医药表示，将在董事会会议后及时发布中期业绩及相关决定的进一步信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196589577","title":"泰凌医药（01011）拟发行约8.48亿股新股以债转股　并提议更换核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=1196589577","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196589577?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:46","pubTimestamp":1786351598,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司8月10日公告称，公司已于2026年6月17日分别与七名认购人签订认购协议，拟以每股0.365港元的价格发行合共847,565,892股新股份，作价合计约3.09亿港元，用以抵销公司于同日应付认购人的等额债务。上述安排及相关交易事项将提交2026年8月28日召开的股东特别大会审议。股东特别大会定于2026年8月28日11时在香港干诺道中168–200号信德中心西座21楼2102室举行。股东名册将于2026年8月25日至8月28日暂停过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147205096","title":"泰凌医药7月股份变动月报表，股本结构保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1147205096","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147205096?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:36","pubTimestamp":1785933369,"startTime":"0","endTime":"0","summary":"2026年8月5日，泰凌医药公布了截至2026年7月31日的股份变动月报表。报告显示，公司本月无新增股份发行、购回及注销活动，全体已发行股份总数保持不变，股本结构整体保持稳定。公司公告披露，截至2026年7月31日，泰凌医药普通股法定/注册股本数量为62,592,500,000股，面值0.0000008美元，对应法定/注册股本50,074美元；优先股法定/注册股本数量为32,500,000股，面值同为0.0000008美元，对应法定/注册股本26美元。公司表示其公众持股量符合香港联交所相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656701583","title":"泰凌医药(01011)转仓市值总计2100.49万港元 占比5.90% 从圣衡金融控股转出5600.00万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2656701583","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656701583?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:47","pubTimestamp":1785804472,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，8月3日，泰凌医药(01011)出现仓位异动，转仓市值总计2100.49万港元，占比5.90%。该公司股东向新永安国际证券转入5600.00万股，从圣衡金融控股转出5600.00万股。2025年度，泰凌医药取得营业收入2415.8万元人民币，同比减少36.36%；归属于上市公司股东的净亏损2604.1万元人民币，亏损同比减少51.20%；基本每股亏损0.0422元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159940","BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186451601","title":"泰凌医药（01011）披露化解“不发表意见”行动计划进展 贷款资本化可削减逾59%债务","url":"https://stock-news.laohu8.com/highlight/detail?id=1186451601","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186451601?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:06","pubTimestamp":1785506784,"startTime":"0","endTime":"0","summary":"泰凌医药7月31日公告，董事会就化解截至2025年12月31日年度财报所涉“持续经营不确定性”不发表意见的行动计划公布季度最新进展，核心包括业务转型及资本结构优化两大方向。拟资本化债务占2025年12月31日集团总债务约人民币4.49亿元的59.38%。泰凌医药称，董事会将继续推进相关措施，以化解持续经营的不确定因素，并在适当时候发布进一步公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160600109","title":"泰凌医药（01011）进一步延迟寄发涉及贷款资本化事项通函","url":"https://stock-news.laohu8.com/highlight/detail?id=1160600109","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160600109?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:26","pubTimestamp":1785497210,"startTime":"0","endTime":"0","summary":"泰凌医药7月31日在港交所公告称，原定于2026年7月31日或之前寄发的有关根据特别授权认购股份以进行贷款资本化事项的通函，现需额外时间落实编制，寄发日期将进一步延迟至2026年8月14日或之前。公告回顾显示，公司曾于2026年6月17日发布涉及贷款资本化的认购协议公告，随后于2026年7月10日公告首次延迟寄发通函。公司指出，延期旨在确保通函内容的准确性与完整性，并将连同股东特别大会通告及代表委任表格一并寄发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152815747","title":"泰凌医药(01011)延迟寄发涉贷款资本化认购事项通函至7月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=1152815747","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152815747?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:41","pubTimestamp":1783672878,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司（01011，下称“泰凌医药”）7月10日发布公告称，公司原计划在6月17日公告日起15个营业日内（即2026年7月10日或之前）寄发有关根据特别授权以贷款资本化方式认购股份的通函。因需额外时间准备并落实通函内若干资料，公司预计通函寄发时间将延迟至2026年7月31日或之前。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194001111","title":"泰凌医药（01011）拟聘中正天恒为新核数师 审计费约88万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1194001111","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194001111?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:42","pubTimestamp":1783420958,"startTime":"0","endTime":"0","summary":"2026年7月7日，泰凌医药公告称，董事会已按香港联交所《上市规则》第13.51条作出决议，拟委任中正天恒会计师有限公司为公司及其附属公司的新核数师，以填补大华马施雲会计师事务所有限公司于2026年6月4日股东周年大会后退任所致的临时空缺。上述委任须待公司股东于即将召开的股东特别大会通过普通决议案后方可生效，新核数师任期将至公司下一届股东周年大会结束为止。1) 中正天恒提出的审计费用；","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649098132","title":"泰凌医药(01011)议决委任中正天恒为新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2649098132","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649098132?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:38","pubTimestamp":1783420702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，经考虑本公司审核委员会(审核委员会)的推荐建议，董事会已议决委任中正天恒会计师有限公司(中正天恒)为本公司新核数师，以填补大华马施云退任后的临时空缺，自股东于股东特别大会(定义见下文)上批准之日起生效，且其任期将直至本公司下一届股东退年大会结束为止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170751155","title":"泰凌医药宣布张博志辞任首席执行官，安迪·景杰接棒","url":"https://stock-news.laohu8.com/highlight/detail?id=1170751155","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170751155?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:53","pubTimestamp":1783414401,"startTime":"0","endTime":"0","summary":"2026年7月3日，泰凌医药发布公告，宣布公司首席执行官张博志已辞去职务，该决定自2026年7月3日起生效。同日，公司董事会任命安迪·景杰为新任首席执行官，接替张博志的工作，任命亦于同日生效。\n此次管理层变动标志着泰凌医药进入新的发展阶段。张博志的离任原因未在公告中详细说明。新任首席执行官安迪·景杰将肩负起领导公司未来战略规划与日常运营的重任。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128893808","title":"中国泰凌医药集团董事会于2026年7月3日批准通过正式举报政策","url":"https://stock-news.laohu8.com/highlight/detail?id=1128893808","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128893808?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:35","pubTimestamp":1783089316,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团董事会于2026年7月3日正式批准并通过了一项公司内部举报政策。此举标志着该公司在完善治理结构、强化内部监督机制方面迈出了重要一步。该政策的建立旨在为员工及利益相关方提供一个安全、保密的渠道，以报告任何可能违反法律法规、公司规章制度或职业道德准则的行为。通过设立明确的举报流程与保护措施，公司期望能够及时发现并处理潜在风险，进一步维护企业诚信与合规运营，保障股东权益及公司的长远健康发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648661986","title":"泰凌医药(01011)：吴静杰获委任为行政总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2648661986","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648661986?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:23","pubTimestamp":1783088598,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，张伯之先生辞任行政总裁职务，以投入更多时间于其个人及其他事务，自2026年7月3日起生效。张伯之先生辞任后不再担任本公司及其任何附属公司的任何职务。吴静杰先生已获委任为本公司行政总裁，自2026年7月3日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168289584","title":"泰凌医药6月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168289584","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168289584?lang=zh_cn&edition=full","pubTime":"2026-07-03 19:39","pubTimestamp":1783078747,"startTime":"0","endTime":"0","summary":"中国泰凌医药集团有限公司于2026年7月3日发布截至2026年6月30日止的月度证券变动报告。报告显示，公司当月在普通股和优先股的注册股本及已发行股份、库存股数方面均无变动，股本保持稳定。月报显示，6月期间并未发生新增发行、购回或注销股份等活动，亦无股份期权或其他股权激励变动。公司确认其已符合香港联交所证券上市规则相关的公众持股量要求，并已遵守相关适用的法律法规。公告由执行董事吴铁签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644747632","title":"泰凌医药(01011)拟推进贷款资本化 折让约20.65%发行合共8.476亿股抵销债务","url":"https://stock-news.laohu8.com/highlight/detail?id=2644747632","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644747632?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:01","pubTimestamp":1781708486,"startTime":"0","endTime":"0","summary":"于本公告日期，杨氏集团于公司已发行股本中拥有约21.23%权益。根据相关认购协议，第二名认购人将认购合共2.508亿股认购股份。贷款资本化完成后，假设完成于2025年12月31日作实，集团于2025年12月31日的债务总额将由约人民币4.49亿元减至人民币1.82亿元。此外，该等债务的利息将仅计算至认购协议日期止且不再进一步计息，而贷款资本化将全额抵销该等债务。清偿该等债务将对集团有利，尤其是由于集团截至2025年12月31日止年度取得亏损人民币2630万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455852.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01011","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642259548","title":"泰凌医药2025年报被出具“不发表意见”后 续聘大华决议遭96.62%高票否决 AI医疗故事尚未贡献一分钱收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2642259548","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642259548?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:01","pubTimestamp":1781233260,"startTime":"0","endTime":"0","summary":"2026年6月4日，港股泰凌医药召开股东周年大会，一项看似常规的“重新委任核数师”的决议案引发轩然大波。最终投票结果显示，关于重新委任大华马施云会计师事务所有限公司为公司核数师的第3项普通决议案，赞成票仅为7，253，850股，反对票高达207，054，239股，以大比例被否决。这是泰凌医药近年最激烈的一次“以票否决”式治理事件。　　大华马施云会计师事务所有限公司已自股东周年大会结束时起退任公司核数师。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-06-12/doc-iniccfxx0342889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ARTY","BK1191","AGIX","CHAT","AIPO","01011","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155149","title":"泰凌医药(01011)：大华马施云退任核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640155149?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:20","pubTimestamp":1780564807,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰凌医药(01011)发布公告，由于有关重新委任大华马施云会计师事务所有限公司为公司核数师之第3项决议案未获股东周年大会通过，大华马施云会计师事务所有限公司已退任公司核数师，自股东周年大会结束时起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01011"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ntpharma.com","stockEarnings":[{"period":"1week","weight":0.3333},{"period":"1month","weight":0.0909},{"period":"3month","weight":-0.3},{"period":"6month","weight":-0.4474},{"period":"1year","weight":-0.4324},{"period":"ytd","weight":-0.4878}],"compareEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":0.0222},{"period":"3month","weight":-0.0032},{"period":"6month","weight":-0.0466},{"period":"1year","weight":0.007},{"period":"ytd","weight":-0.0044}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国泰凌医药集团有限公司是一家主要提供医药产品销售及分销服务的投资控股公司。该公司通过两个分部运营业务。数字服务分部主要提供与骨健康知识的市场推广及宣传有关的数字服务。销售代理分部主要提供代理服务为代理客户向外部客户销售医疗及健康相关产品服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.003177},{"month":2,"riseRate":0.466667,"avgChangeRate":0.045108},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034671},{"month":4,"riseRate":0.6,"avgChangeRate":0.215361},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.031879},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.023905},{"month":7,"riseRate":0.375,"avgChangeRate":-0.017618},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.062823},{"month":9,"riseRate":0.4,"avgChangeRate":0.038353},{"month":10,"riseRate":0.4,"avgChangeRate":-0.009707},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.071764},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.020063}],"exchange":"SEHK","name":"泰凌医药","nameEN":"NT PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰凌医药,01011,泰凌医药股票,泰凌医药股票老虎,泰凌医药股票老虎国际,泰凌医药行情,泰凌医药股票行情,泰凌医药股价,泰凌医药股市,泰凌医药股票价格,泰凌医药股票交易,泰凌医药股票购买,泰凌医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰凌医药(01011)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰凌医药(01011)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}